免疫受损干燥综合征患者对重组带状疱疹疫苗的体液应答强度较低:随机双盲安慰剂对照试验证据
该随机双盲安慰剂对照研究纳入67例免疫受损干燥综合征(SjD)患者和201例年龄/性别匹配的非免疫抑制对照,评估重组带状疱疹疫苗(RZV)的免疫原性和安全性。SjD患者按D0和D42接种疫苗或安慰剂,结果显示SjD组血清转化率90.6%低于对照99.5%(P<0.001),GMT和倍数增长GMT均显著低于对照,但细胞应答组间相当,疾病活动稳定且无严重疫苗相关不良事件。
要点
- 免疫受损SjD患者接种RZV后血清转化率90.6%,低于对照的99.5%(P<0.001)。
- SjD组GMT为7.1 mIU/mL、倍数增长GMT为23.9,均显著低于对照(P<0.001)。
- 细胞应答在SjD与对照间相当(P>0.05),疾病活动稳定且无严重疫苗相关不良事件。
核心结论
- RZV在免疫受损SjD患者中安全性良好,但体液应答强度显著低于非免疫抑制对照,可能影响长期免疫保护。
研究设计与样本
- 随机双盲安慰剂对照研究,纳入67例免疫受损SjD患者和201例年龄/性别匹配的非免疫抑制对照。
- SjD患者随机接受疫苗(SjD-V)或安慰剂(SjD-P)于D0和D42接种,SjD-P在揭盲后D84和D126接种;对照于D0和D42接种。
主要发现
- SjD组血清转化率90.6%低于对照99.5%(P<0.001)。
- SjD组GMT为7.1(5.3-9.6)mIU/mL,低于对照12.6(11.4-13.9)mIU/mL(P<0.001)。
- SjD组倍数增长GMT为23.9(16.0-35.8),低于对照70.4(58.8-84.4)(P<0.001)。
- 细胞应答在SjD与对照间相当(P>0.05)。
- 疾病活动、SjD症状/生物学参数保持稳定(P>0.05),无严重疫苗相关不良事件。
关键数值与推荐
- 血清转化定义为第二剂RZV后6周抗gE浓度较基线≥4倍增加。
- gE特异性CD4+ T细胞在约10%参与者中计数。
临床怎么用
- 免疫受损SjD患者可安全接种RZV,但需认识到其体液应答强度较低,可能需要优化免疫策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Immunocompromised Sjögren's disease-(SjD) patients are susceptible to herpes zoster reactivated infection-(HZ/shingles), yet data on the recombinant zoster vaccine-(Shingrix®/RZV) in these patients are limited. OBJECTIVES: To assess RZV humoral/cellular immunogenicity and safety in immunocompromised SjD patients. METHODS: Randomized double-blind placebo-controlled study comprising 67 immunocompromised SjD patients and 201 age-/sex-balanced non-immunosuppressed controls. SjD patients were randomized to receive vaccine-(SjD-V) or placebo-(SjD-P) on day-0-(D0) and D42. SjD-P were immunized after unblinding on D84 and D126. Controls were vaccinated on D0 and D42. Adverse events-(AEs) and disease activity were monitored. Humoral immunogenicity was assessed by anti-gE concentrations, with seroconversion defined as ≥4-fold increase from baseline to 6-weeks after the 2nd RZV dose. gE-specific CD4+ T cells were counted in ≅10% of participants. Vaccine impact on SjD symptoms/biological parameters was explored. RESULTS: SjD and controls were comparable regarding age [55.0 (48.3-63.8) vs. 55.0 (52.0-64.0) years; P = 0.087] and sex (P = 0.303). Seroconversion rate was lower in SjD than controls (90.6% vs. 99.5%; P < 0.001), with reduced geometric-mean-titer-(GMT) [7.1 (5.3-9.6) vs. 12.6 (11.4-13.9) mIU/mL; P < 0.001] and factor-increase-GMT [23.9 (16.0-35.8) vs. 70.4 (58.8-84.4); P < 0.001] in SjD. The cellular response was comparable between SjD patients and controls (P > 0.05). Disease activity, SjD symptoms/biological parameters remained stable (P > 0.05). No serious vaccine-related AEs occurred. CONCLUSION: RZV showed a favorable safety profile in immunocompromised SjD patients. Despite the high seroconversion rate, the response was significantly lower in magnitude compared to controls. This may compromise long-term immunity, underscoring the need for optimizing immune responses in this population (ClinicalTrials.gov-NCT05879419).
引用
- Pasoto SG, Ribeiro TO, Aikawa NE, et al. Lower magnitude of humoral response to recombinant herpes zoster vaccine in immunocompromised Sjögren's disease patients: evidence from a randomized double-blinded placebo-controlled trial. Semin Arthritis Rheum. 2026. PMID: 41932224. doi:10.1016/j.semarthrit.2026.152974
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。